Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAMHD1 siRNA
- Development stage
- Preclinical
- Lead developer
- Keimyung University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
SAMHD1 siRNA is a small interfering RNA designed to silence the expression of the SAMHD1 (sterile alpha motif and HD domain-containing protein 1) gene. SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that regulates cellular dNTP pools and has been implicated in viral defense and cell cycle regulation. In the context of oncology, specifically clear cell renal cell carcinoma (ccRCC), SAMHD1 has been identified as an oncogene that promotes cell migration and metastasis. Mechanistically, SAMHD1 contributes to the formation of an endosomal complex by binding to cortactin, which stimulates endosomal focal adhesion kinase (FAK) signaling and activates Rac1, leading to lamellipodia formation. SAMHD1 siRNA is primarily used as a research tool to inhibit this pathway, thereby reducing the motility and invasive potential of cancer cells in preclinical models.
- Other names
- siRNA targeting SAMHD1SAMHD1-targeting siRNASAMHD-1-targeting siRNASAMHD 1-targeting siRNA
02
Targets
SAMHD1 (Sterile alpha motif and HD domain-containing protein 1)
Beyond the preview
Go deeper on SAMHD1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAMHD1 siRNA.